**Organelle facts**•Mitochondrial protein synthesis requires several mitochondrial and nuclear-encoded factors for optimal translation.•The clinical presentation of diseases due to defective mitochondrial protein synthesis is very variable and tissue specific presentations are common.•The reasons behind the tissue specificity are largely unknown.•Besides mitochondrial tRNA mutations and mtDNA deletions or depletion, autosomal recessive mutations have been reported in genes encoding ribosomal proteins, ribosome assembly proteins, mitochondrial aminoacyl-tRNA synthetases, tRNA modifying enzymes and initiation, elongation and termination factors of translation.•Frequent and clinically recognisable genetic causes of human diseases due to impaired mitochondrial translation are caused by mutations in mitochondrial tRNA synthetase and tRNA modifying genes.•The potential interaction between cytosolic and mitochondrial translation requires further investigations.

1. Introduction {#sec0005}
===============

Mitochondrial diseases affect at least 1 in 5000 of the population and produce diverse clinical phenotypes often presented as multi-systemic disorders ([@bib0075; @bib0340; @bib0310]). In addition to the nucleus, human cells also harbour DNA in the mitochondria (mtDNA), which is essential for cell viability ([@bib0305]). This small (16.5 kb) genome is found in multiple copies in mitochondria, the subcellular organelles that often constitute more than 20% of the total cell volume. OXPHOS (oxidative phosphorylation) is responsible for the production of ATP by generating a proton gradient across the inner membrane of the mitochondria which is used by the mammalian cells ([@bib0125]). The mitochondrial OXPHOS system comprises around 150 different proteins out of which only 13 polypeptide subunits are encoded by the mtDNA. In addition, the mtDNA encodes the small and large rRNAs, and 22 distinct mitochondrial tRNAs that are necessary for the translation of only the mitochondrial-encoded proteins ([@bib0275; @bib0230; @bib0055]). The nuclear-encoded subunits of the respiratory chain (RC) complexes as well as proteins that are inevitable for normal mitochondrial protein synthesis (such as OXPHOS assembly, mtDNA metabolism and maintenance, mitochondrial cofactor biosynthesis, mitoribosomal subunits and assembly factors, regulators of mitochondrial expression and translation, etc.) are encoded by the nuclear genome (nDNA) and synthetised in the cytosol before transported into the organelle ([@bib0310]). The mitochondrial ribosomal proteins assemble with mitochondrial ribosomes 12S rRNA and 16S rRNA to form the mitochondrial ribosome ([@bib0205]). Lately it was also reported that import of 5S rRNA is also transported to the mitochondria being an essential component of the mitochondrial ribosomes ([@bib0270]).

2. Organelle function {#sec0010}
=====================

The components responsible for the proper mitochondrial translation are different from their cytosolic counterparts and they are more related to those of bacteria however the mechanisms of the translation follows the same major steps: initiation, elongation, termination and recycling of the ribosome ([@bib0050]) ([Fig. 1](#fig0005){ref-type="fig"}).

2.1. Initiation {#sec0015}
---------------

The process of mitochondrial translation starts with the formation of the initiation complex. The separation of the two mitochondrial ribosomal subunits (28S and 39S) ([@bib0170]) allow this complex to be formed which consists of the 28S subunit, mRNA and fMET-tRNA and IF2/3~mt~ ([@bib0165; @bib0045]). This is followed by the entrance of the mRNA into the IF3~mt~:28S subunit complex. IF3~mt~ is thought to support the correct position of mRNA to bind the small subunit at the peptidyl (P) site of the mitoribosome. When the appropriate start codon is present, the formylmethionin-tRNA can bind to the first codon with the help of IF2~mt~. The association of the mitoribosome stimulates the release of the initiation factors and the elongation on the 55S ribosome commence. MTFMT is critical for efficient human mitochondrial translation and reveal a human disorder of Met-tRNA(Met) formylation ([@bib0300; @bib0190]).

2.2. Elongation {#sec0020}
---------------

To coordinate accurate and specific codon anti-codon pairing, mitochondrial elongation factor (EF-Tu~mt~-GTP) and an amino-acylated tRNA arrives to the A-site of the mitoribosome. Upon correct codon-anticodon pairing the EF-Tu~mt~-GDP leave the mitoribosome and the aminoacyl-tRNA moves into the P site where peptide bond formation is catalysed extending the growing polypeptide chain. EF-Ts~mt~ plays a role as a nucleotide exchange factor and converts EF-Tu~mt~ to an active form (EF-Tu~mt~-GTP). The GTP bound EFG1~mt~ catalyses the translocation of the ribosome during the A and P site tRNAs move to the P and exit (E) sites of the mitoribosome. This elongation step repeats itself until the stop codon (UAA, UAG, AGA or AGG) is encountered in the A-site. Mutation of the mitochondrial elongation factors typically associated with encephalopathy and other organ involvement (liver, heart). Clinical symptoms are present in early infancy and the affected children die early ([@bib0315; @bib0265; @bib0060; @bib0280; @bib0285]).

2.3. Termination {#sec0025}
----------------

The mitochondrial release factor (mtRF1a) recognises the stop codon and binds to the mitoribosome, induces hydrolysis of the peptidyl-tRNA bond in the A-site releasing the mature protein from the site. Other termination release factors such as mtRF1, C12orf65 and ICT1 are also thought to play an essential role in the termination ([@bib0210]). As a last step mitochondrial recycling factors (mtRRF1 and mtRRF2) translocate to the A-site to induce the release of the mRNA ([@bib0055]). Up to date only the *C12orf65* has been identified as a disease causing gene. Affected patients develop optic atrophy and ophthalmoplegia with Leigh syndrome ([@bib0010]).

2.4. Regulatory mechanisms {#sec0030}
--------------------------

The expression of mitochondrial proteins is regulated by their own translational activators that bind mitochondrial mRNAs usually to their 5'-untranslated regions, and each mitochondrial mRNA has its own translational activator(s), which has been first shown in yeast ([@bib0140]). Recent studies showed that these translational activators can be part of a feedback control loops which only permit translation if the downstream assembly of nascent translation products can occur ([@bib0140]). Recently mutations in nuclear-encoded translational activators of mitochondrial proteins such as *TACO1* were also implicated in human disease ([@bib0325]). A regulatory role of aminoacyl-tRNA synthetases has been suggested in both cytosolic and mitochondrial translation ([@bib0335]) and other factors, such as MTERF3 has been implicated to coordinate crosstalk between transcription and translation for the regulation of mammalian mtDNA ([@bib0330]).

3. Cell Physiology {#sec0035}
==================

Impaired mitochondrial translation usually results in severe combined respiratory chain dysfunction through deficient function of all mtDNA-encoded proteins however some nuclear genes have been shown to alter the translation of single mitochondrial-encoded proteins. The defective mitochondrial proteins lead to deficient ATP production, and cellular energy deficit.

Human cells contain 17 cytoplasmic ARS polypeptides, including the bifunctional glutamyl-prolyl-tRNA synthetase (EPRS), and 18 mitochondrial ARS2 enzymes. Three ARS genes encode proteins with dual localisation, present both in the cytoplasm and mitochondria (GARS, KARS, QARS), and the transport of the mitochondrial isoforms is ensured by a mitochondrial targeting signal.

Beside disorders due to impaired mitochondrial translation, several human disorders are caused by altered cytosolic translation ([@bib0335]). Interestingly these diseases also lead to tissue specific clinical presentations mainly affecting brain, spinal cord and peripheral neurons, illustrated by clinical presentations such as Charcot--Marie--Tooth disease (CMT), distal hereditary motor neuropathies (dHMN) or leukoencephalopathy with vanishing white matter (VWM). Further implications of altered translation are highlighted by variable and complex clinical presentations, including diseases of eye, cartilage, skin, hair and even cancer ([Table 1](#tbl0005){ref-type="table"}).

4. Organelle pathology {#sec0040}
======================

As it was predicted, mutations in the nuclear genes coding for various components of the translation machinery could give rise to a wide spectrum of diseases and phenotypes ([@bib0055]) ([Table 1](#tbl0005){ref-type="table"}). Mitochondrial protein synthesis requires several nuclear-encoded factors, such as ribosomal proteins, ribosome assembly proteins, aminoacyl-tRNA synthetases, tRNA modifying enzymes and initiation, elongation and termination factors of translation ([@bib0230]) ([Fig. 1](#fig0005){ref-type="fig"}). Autosomal recessive mutations have been reported in several of these factors in association with variable clinical presentations ([@bib0055]). Here we note, that disorders of mitochondrial protein synthesis usually result in combined RC deficiencies and associated with abnormal mitochondria (ragged red fibres, COX negative fibres) on histology. However a defect of translation activation factors or post-transcriptional regulators of mammalian mtDNA expression may cause impairment in the stability of certain mitochondrial transcripts, as reported in patients with *TACO1* and *LRPPRC* deficiency, respectively ([@bib0325; @bib0130]). Because these defects appear to affect only a single OXPHOS enzyme (COX), these patients show isolated COX deficiency.

4.1. Defective mitochondrial translation due to mtDNA mutations {#sec0045}
---------------------------------------------------------------

Frequent causes of impaired mitochondrial translation are mtDNA rearrangements (e.g. Kearns--Sayre syndrome) that affect mitochondrial tRNA and/or rRNA genes or single mt-tRNA point mutations. About half of the mtDNA mutations causing diseases in humans occur in tRNA genes (MELAS, MERRF, etc.) and the heterogeneous clinical manifestations usually reflect variable heteroplasmy ([@bib0305; @bib0125]). Homoplasmic tRNA mutations with variable penetrance and clinical presentations also occur and suggest the role of genetic or epigenetic modifiers in mitochondrial translation ([@bib0295]). Although most of these conditions are progressive and fatal, reversible infantile cytochrome c oxidase deficiency myopathy (or reversible infantile respiratory chain deficiency), due to a homoplasmic mt-tRNA^Glu^ mutation stands out by showing spontaneous recovery ([@bib0145]).

4.2. Defective mitochondrial translation due to nuclear gene defects {#sec0050}
--------------------------------------------------------------------

The currently defined disorders caused by nuclear defects of mitochondrial protein synthesis are usually early-onset, severe, often fatal diseases ([Table 1](#tbl0005){ref-type="table"}) with extremely variable clinical presentations, and the reason behind is still unclear. Patients with translation elongation factor or mitochondrial ribosomal protein defects had an early age of onset and a severe multisystem disease with symptoms already present at birth or even prenatal in a few cases ([Table 1](#tbl0005){ref-type="table"}).

The extreme variability and relative strict tissue specificity of the diseases caused by mutations in mitochondrial tRNA synthetase genes illustrate the importance of understanding the factors influencing mitochondrial translation in different tissues.

4.3. Neurological presentations {#sec0055}
-------------------------------

Some genes are selectively important in specific neuronal populations, as exemplified by leukoencephalopathy with brainstem and spinal cord involvement (LBSL) due to mutations in the mitochondrial aspartyl-tRNA synthetase 2 (*DARS2*), or pontocerebellar hypoplasia caused by argynyl tRNA synthetase 2 (*RARS2*) defect ([@bib0250; @bib0085]). Mutations in the glutamyl-tRNA synthetase (*EARS2*) cause early onset severe neurological disease (leukoencephalopathy involving the thalamus and brainstem with high lactate, LTBL) ([@bib0290; @bib0115]). MTFMT deficiency leads to (relatively mild) Leigh syndrome with or without optic atrophy ([@bib0300; @bib0190]).

4.4. Cardiac presentations {#sec0060}
--------------------------

Recently autosomal recessive mutations were reported in the *AARS2* and *MTO1* genes in patients with infantile hypertrophic cardiomyopathy. *MTO1* encodes the enzyme that catalyzes the 5-carboxymethylamino-methylation of the wobble position in mt-tRNA^Glu^, mt-tRNA^Gln^ and mt-tRNA^Lys^ ([@bib0115]). Patents with clinically indistinguishable clinical presentation of fatal infantile hypertrophic cardiomyopathy had mutations in the mitochondrial alanyl-tRNA synthetase 2 (*AARS2*) gene ([@bib0120]).

4.5. Hepatic presentations {#sec0065}
--------------------------

Autosomal recessive mutations in the tRNA 5-methylaminomethyl-2-thiouridylate methyltransferase (*TRMU*), which is responsible for 2-thiouridylation of the mt-tRNA^Glu^, mt-tRNA^Gln^ and mt-tRNA^Lys^ cause a severe but reversible infantile hepatopathy ([@bib0345; @bib0245; @bib0240]). Infants with reversible hepatopathy develop symptoms between 2 and 4 months of age, but if they survive this phase of liver failure, they recover and develop normally ([@bib0245]). The disease course and age of manifestation in TRMU deficiency shows remarkable similarities to reversible infantile myopathy and recent studies suggest that infantile cysteine concentrations may be important for the reversibility of both of these diseases ([@bib0025]).

4.6. Haematological presentations {#sec0070}
---------------------------------

As a further complication of mt-tRNA synthetase dysfunction, the involvement of blood cells has been implicated by mutations in *PUS1*, resulting in mitochondrial myopathy, lactic acidosis and sideroblastic anaemia (MLASA) ([@bib0035]). Mitochondrial tyrosyl-tRNA synthetase 2 (*YARS2*) mutations have been also identified in families with MLASA, very similar, but earlier onset compared to the phenotype caused by deficiency of a mt-tRNA modifying enzyme PUS1 ([@bib0055]).

4.7. Other presentations {#sec0075}
------------------------

Other characteristic, rare diseases are HyperUricemia, Pulmonary hypertension, Renal failure and Alkalosis (HUPRA) syndrome, which is caused by mutations in the mitochondrial seryl-tRNA synthetase 2 (*SARS2*) ([@bib0020]) and Perrault syndrome, characterised by ovarian dysgenesis and sensorineural hearing loss due to mutations in the mitochondrial histidyl-tRNA synthetase 2 (*HARS2*) ([@bib0195]) and leucyl-tRNA synthetase 2 (*LARS2*) ([@bib0200]).

5. Future outlook {#sec0080}
=================

Despite the rapid advances in technologies and the growing number of human disease genes and studies on mechanisms of mammalian mitochondrial translation, its regulation still remains largely unexplored. The variety and intriguing tissue and cell-type specific clinical presentations in both mitochondrial and cytosolic translation, and the dual function of some ARS enzymes suggest substantial interaction and overlap between these two protein synthesis pathways, which have not been extensively studied to date. Due to the abundant proteins and factors required for maintaining accurate mitochondrial translation, it is a challenge to identify the genetic defect in all cases. However rapid development of genetic technologies (next generation sequencing) resulted in a dynamic improvement in genetic diagnosis. Although there is a phenotypic diversity in patients with mitochondrial translation deficiencies, we observed some emerging clinical subgroups ([@bib0160]), which recently turned out to be associated with specific genetic defects. In patients with neurological presentation tRNA synthetases or tRNA modifying factors are the most likely cause of disease. *AARS2* and *MTO1* mutations are preferentially associated with cardiomyopathy, mutations in *TRMU* present with infantile, reversible liver failure, *YARS2* and *PUS1* mutations lead to sideroblastic anaemia and myopathy, and *RMND1* deficiency cause deafness, myopathy, renal involvement and a severe biochemical defect ([Table 1](#tbl0005){ref-type="table"}).

Defining the exact pathomechanisms will suggest new avenues for treatment in these disorders, as it has been recently studied in reversible COX deficiency myopathy and TRMU deficiency ([@bib0025]). Downregulation of TRMU that is required for 2-thiouriylation in cells from patient with RIRCD led to a reduction in levels of mt-tRNA^Glu^ thiolation resulting in a defect of mitochondrial protein synthesis. Cysteine is essential for normal thiolation and supplementation of L-cysteine improved mitochondrial gene translation not only in TRMU but also in RIRCD cells. Interesting experimental progresses are being pursued towards gene therapeutic approaches for mitochondrial translational disorders. Engineered human mitochondrial tRNAs and mRNAs -- containing RP import sequence -- can be efficiently imported into the mitochondria where they restore translation ([@bib0355]). The use of exosomes the body\'s own vehicle mechanism for delivering protein and genetic biomarkers are also promising and new avenues are being identified. Recently it has been shown that mRNAs for most tRNA synthetases can be detected in exosomes ([@bib0350]). The detection of mutations in factors involved in mitochondrial translation widens our understanding of mitochondrial disease and highlights basic molecular mechanisms.

![Schematic overview of human genes involved in mitochondrial protein synthesis defects. Prior to mitochondrial protein synthesis the mtDNA needs to be maintained and correctly replicated and transcribed. Mutations within nDNA-encoded genes responsible for these functions lead to mtDNA deletion(s) and depletion. Several other proteins also have to be imported into the mitochondria for accurate mitochondrial translation processes. These nuclear encoded genes are categorised into different groups based on their role in the translational machinery. The first group of genes (highlighted in red) are the genes that are involved in cytosolic translation. Some of these nuclear genes (*GARS*, *KARS* (*marked with black stars*)) are transported to the mitochondria and also function as mitochondrial aminoacyl t-RNA synthetase (ARS). Nuclear genes involved in mt-tRNA modification are: *MTO1*, *PUS1*, *TRMU* and *MTFMT* (highlighted in purple) (the functions of the genes are shown and labelled as (**1**). Up to date 10 mitochondrial ARSs have been found to cause translational deficiencies in humans. These genes are *DARS2*, *RARS2*, *EARS2*, *MARS2*, *FARS2*, *AARS2*, *YARS2*, *SARS2*, *HARS2* and *LARS2* (highlighted in dark blue) (**2**). Nuclear genes encoding for ribosomal proteins and involved in impaired mitochondrial translation are *MRPL3*, *MRPS16*, *MRPS22*, *MRPL12* and *MRPL44* (light blue) (**3**). Genes represented in green are responsible for the mitochondrial translation steps: initiation, elongation and termination (**4**): *RMND1*, *TUFM*, *TSFM*, *GFM1*, *C12orf65*. Nuclear genes such as translational activators and mRNA stability factors (*LRPPRC*, *TACO1* and *MTPAP*) also involved in impaired mitochondrial protein synthesis (**5**). For the formation of the respiratory chain (RC) complexes both nuclear and mitochondrial DNA are required. nDNA-encoded RC subunit genes and RC assembly factors need to be synthetised, transported to the mitochondrial matrix and assembled into functional enzyme complexes with the 13 mDNA-encoded proteins. These 13 proteins are represented within each complex (CI: ND1, ND2, ND3, ND 4L, ND4, ND5, ND6; CIII: CYTB; CIV: COX1, COX2, COX3; CV: ATPase6, ATPase8) (**6**). Schematic drawing of the mitochondrial genome (**7**) showing the 13 proteins, 2 r-RNA, 22 t-RNA regions and the control region. Mutations for MELAS, MERRF and for common deletions are shown in the diagram. Associated clinical phenotypes with the gene mutations mentioned above are detailed in [Table 1](#tbl0005){ref-type="table"}.](gr1){#fig0005}
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Nuclear DNA mutations involved in impaired mitochondrial translation and associated diseases in human. Sources: OMIM (Online Mendelian Inheritance in Man).

  Nuclear genes involved in impaired cytosolic translation                                                                                                                                                                                                                                                                                                                                                        
  ---------------------------------------------------------- ---------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------- ----------------------------- --------------------------------
  *EIF2AK1-5*                                                eIF2B subunits α--ɛ                                                                            Vanishing white matter; childhood ataxia with central nervous system hypomyelination (chronic progressive, an episodic encephalopathy)                                                    Childhood to adult age        604032                        [@bib0175; @bib0320]
  *EIF2AK3*                                                  eIF2 α kinase PERK                                                                             Wolcott--Rallison syndrome (diabetes mellitus, epiphyseal dysplasia, kidney and liver dysfunction, mental retardation, central hypothyroidism and dysfunction of the exocrine pancreas)   Neonatal or early childhood   604032                        [@bib0070]
  *GARS YARS KARS AARS*                                      Glycyl-tRNA synthetase tyrosyl-tRNA synthetase lysyl-tRNA synthetase alanyl-tRNA synthetase.   Dominant intermediate Charcot--Marie--Tooth type C (slowly progressive mixed demyelinating-axonal neuropathy) or hereditary motor neuropathy                                              Childhood to adult age        600287 603623 601421 601065   [@bib0005][@bib0155][@bib0225]
  *RPS19 RPS24*                                              Ribosomal protein S19 ribosomal protein S24                                                    Diamond--Blackfan anaemia (abnormalities of the thumb, short stature, ventricular septal defects, kidney hypoplasia and congenital glaucoma)                                              From birth                    603474 602412                 [@bib0080; @bib0110]
  *RMRP*                                                     Mitochondrial RNA proc. endoribonuclease                                                       Cartilage-hair hypoplasia                                                                                                                                                                 Neonatal, infantile           157660                        [@bib0215]
  *DKC1*                                                     Dyskerin                                                                                       X-linked dyskeratosis congenita (ectodermal abnormalities, bone marrow failure and susceptibility to cancer)                                                                              From birth                    300126                        [@bib0135]
  *SBDS*                                                     Shwachman--Bodian--Diamond syndrome protein                                                    Shwachman--Diamond syndrome (exocrine pancreatic insufficiency, bone marrow dysfunction, skeletal abnormalities and short stature)                                                        From birth                    607444                        [@bib0030]

  Nuclear genes involved in impaired mitochondrial translation -- tRNA-modifying enzymes                                                                                                                                                            
  ---------------------------------------------------------------------------------------- -------------------------------------------------------------- -------------------------------------------------------------- ----------------- -------- ---------------------------------
  *PUS1*                                                                                   Pseudouridine synthase                                         Myopathy, lactic acidosis and sideroblastic anaemia (MLASA1)   Early childhood   608109   [@bib0035]
  *TRMU*                                                                                   tRNA 5-methylaminome-thyl-2-thiouridylate methyl-transferase   Reversible infantile liver failure                             Infantile         613070   [@bib0345; @bib0095][@bib0245];
  *MTO1*                                                                                   Mitoch. translation optimisation 1 homolog                     Hypertrophic cardiomyopathy and lactic acidosis                Infantile         614702   [@bib0115]
  *MTFMT*                                                                                  Mitoch. methionyl-tRNA formyltransferase                       Leigh syndrome                                                 Early childhood   611766   [@bib0300][@bib0190]

  Nuclear genes involved in impaired mitochondrial translation -- ribosomal proteins                                                                                                                                        
  ------------------------------------------------------------------------------------ ------------------------------------- ------------------------------------------------------------------------- ----------- -------- --------------------------------
  MRPL3                                                                                Mitochondrial ribosomal protein L3    Hypertrophic cardiomyopathy and psychomotor retardation                   Infantile   614582   [@bib0100]
  *MRPS16*                                                                             Mitochondrial ribosomal protein S16   Corpus callosum agenesia, hypothonia and fatal neonatal lactic acidosis   Neonatal    610498   [@bib0180]
  *MRPS22*                                                                             Mitochondrial ribosomal protein S22   Cornelia de Lange-like syndrome oedema, cardiomyopathy and tubulopathy    Neonatal    611719   [@bib0235; @bib0280; @bib0285]
  *MRPL12*                                                                             Mitochondrial ribosomal protein L12   Growth retardation and neurological deterioration                         Neonatal    602375   [@bib0255]
  *MRPL44*                                                                             Mitochondrial ribosomal protein L44   Hypertrophic cardiomyopathy                                               Neonatal    611849   [@bib0040]

  Nuclear genes involved in impaired mitochondrial translation -- aminoacyl-tRNA synthetases                                                                                                                                                                       
  -------------------------------------------------------------------------------------------- -------------------------------- ------------------------------------------------------------------------------------------------ ------------------------ -------- ----------------------
  *DARS2*                                                                                      Aspartyl-tRNA sythetase 2        Leukoencephalopathy with brainstem and spinal cord involvement (LBSL)                            Childhood or adulthood   610956   [@bib0250]
  *RARS2*                                                                                      Arginyl-tRNA synthetase 2        Pontocerebellar hypoplasia type 6 (PCHD-6)                                                       Neonatal                 611523   [@bib0085]
  *EARS2*                                                                                      Glutamyl-tRNA synthetase 2       Leukoencephalopathy with thalamus and brainstem involvement and high lactate (LTBL)              Infantile                612799   [@bib0290]
  *MARS2*                                                                                      Methionyl-tRNA synthetase 2      Autosomal recessive spastic ataxia with leukoencephalopathy                                      Juvenile or adulthood    609728   [@bib0015]
  *FARS2*                                                                                      Phenylalanyl-tRNA synthetase 2   Alpers syndrome, encephalopathy, epilepsy, lactic acidosis                                       Neonatal and infantile   611592   [@bib0090; @bib0260]
  *AARS2*                                                                                      Alanyl-tRNA synthetase 2         Hypertrophic cardiomyopathy                                                                      Infantile                614096   [@bib0120]
  *YARS2*                                                                                      Tyrosyl-tRNA synthetase 2        Myopathy, lactic acidosis, and sideroblastic anaemia (MLASA2)                                    Infantile                613561   [@bib0220]
  *SARS2*                                                                                      Seryl-tRNA synthetase 2          HUPRA syndrome (hyperuricemia, pulmonary hypertension, renal failure in infancy and alkalosis)   Infantile (4 months)     613845   [@bib0020]
  *HARS2*                                                                                      Histidyl-tRNA synthetase 2       Perrault syndrome (sensorineural deafness, ovarian dysgenesis)                                   Juvenile or adulthood    600783   [@bib0195]
  *LARS2*                                                                                      Leucyl-tRNA synthetase 2         Perrault syndrome (sensorineural deafness, ovarian dysgenesis)                                   Juvenile                 604544   [@bib0200]

  Nuclear genes involved in impaired mitochondrial translation -- initiation, elongation and termination factors                                                                                                                                                  
  ---------------------------------------------------------------------------------------------------------------- ------------------------------------------------- ----------------------------------------------------------------------- ----------- -------- --------------------------------
  *RMND1*                                                                                                          RMND                                              Deafness, myopathy, renal involvement and a severe biochemical defect   Neonatal    614917   [@bib0105]: [@bib0150]
  *TUFM*                                                                                                           Elongation factor Tu, mitochondrial (EF-TU~mt~)   Lactic acidosis, leukoencephalopathy and polymicrogyria                 Neonatal    610678   [@bib0315]
  *TSFM*                                                                                                           Elongation factor Ts, mitochondrial (EF-Ts~mt~)   Encephalomyopathy, hypertrophic cardiomyopathy                          Neonatal    610505   [@bib0265]
  *GFM1*                                                                                                           Elongation factor G 1, mitochondrial (EFG1~mt~)   Encephalopathy with or without liver involvement                        Neonatal    609060   [@bib0060; @bib0280; @bib0315]
  *C12orf65*                                                                                                       Chromosome 12 open reading frame 65               Leigh syndrome, optic atrophy, ophthalmoplegia                          Infantile   613559   [@bib0010]

  Nuclear genes involved in impaired mitochondrial transaltion -- translation activators and mRNA stability factors                                                                                                                                              
  ------------------------------------------------------------------------------------------------------------------- --------------------------------------------------- ------------------------------------------------ ---------------------------- -------- ------------
  *LRPPRC*                                                                                                            Leucine-rich PPR-motif containing protein           Leigh syndrome French--Canadian variant (LSFC)   Infantile                    220111   [@bib0185]
  *TACO1*                                                                                                             Translational activator of cytochrome c oxidase 1   Late-onset Leigh syndrome                        Juvenile                     612958   [@bib0325]
  *MTPAP*                                                                                                             Mitochondrial poly-A polymerase                     Progressive spastic ataxia with optic atrophy    Juvenile (early childhood)   613672   [@bib0065]
